一个弃医从药的多面手。一个门门通样样精的奇才。一个惟愿以一己之躯架起基础化学与生命本质之间的桥梁的傻瓜型科研工作者。

主要经历

1989-1996 白求恩医科大学七年制硕士班，获得医学学士、硕士学位

1996-1999 大连铁路医院，医师

1999-2002 大连理工大学生物工程系，博士, 2002年获得工学博士学位

2002至今  大连理工大学精细化工系，副教授，化学生物学课题组负责人

2006-2007 美国哈佛大学化学与化学生物学系博士后。

2010-2014 大连理工大学化工与环境生命学部，化学学院，副教授

2014 大连理工大学化工与环境生命学部，化学学院，教授

主要研究方向：

1.      小分子靶向抗癌药的研发

2.      Bcl-2等肿瘤靶标的可视化研究

3.      肿瘤信号转导通路与药靶网络

基金：

1．国家自然科学基金（82073703）亚型特异性Hsp70抑制剂的设计合成、和抗肿瘤分子标志物研究。2021,1-2024,12. 项目负责人。

2．大工辽肿医工合作项目：p53—Bcl-2轴在卵巢上皮癌顺铂耐药中的分子机制研究和逆转耐药的原创抗癌先导药物发现。项目负责人。（DUT20YG133）

3．大连市科技创新基金“一带一路”国际科技合作项目(2019J12SN51)：Bcl-2抑制剂类靶向抗癌药的创制。项目负责人。

4．国家自然科学基金（81570129）Bcl-2家族蛋白在慢性粒细胞白血病Bcr/Abl非依赖型耐药中的机制研究。2016，1-2019，12。项目负责人。

5．国家自然科学基金（81430083）重点项目：基于Bcl-2家族蛋白相互作用网络研究的多靶标抗肿瘤化合物。2015-2019。合作单位负责人。

6．国家自然科学基金（21372036）基于片段的广谱Bcl-2抑制剂研究——分子设计和优化的定量活性评价。2014,1-2017,12。项目负责人。

7．国家自然科学基金（30772622）新的有机小分子BH3 模拟物的分子特征和构效关系。2008年-2010年。项目负责人。

8．国家自然科学基金(30400106)Hg²⁺荧光分子探针和单个活细胞内Hg2+的可视化。2005年-2008年。项目负责人。

 

专利转让

已经转让四项成果专利：

      1．苊并杂环类化合物及其诱导细胞凋亡和抗肿瘤的应用。ZL200410050449.5

2．苊并杂环类化合物、其环糊精包合物和环糊精配结物以及它们在制备Bcl-2家族蛋白抑制剂中的应用。CN200910209961.2.

3. 苊并杂环类化合物、其环糊精包合物和环糊精配结物以及它们在制备Bcl-2家族蛋白抑制剂中的应用。PCT/CN2009/074602.

4. Bcl-2家族蛋白抑制剂，其环糊精包合物、配结物及其在制备Bcl-2家族蛋白抑制剂中的应用 PCT/CN2010/075521.

 

发表论文

1.        Ziqian Wang, Xiaodong Zhang, Hong Zhang, Yao Tang, Hao Pan, Hang Wang, Tong Ji, Yafei Guo,Qishuang Gao, Ting Song,* and Zhichao Zhang*. Discovery of a Fluorogenic Probe for In Situ Pyruvate Kinase M2 Isoform (PKM2) Labeling through Chemoselective SNAr with a Binding Site Lysine Residue. Anal. Chem. 2021, 93, 9669−9676

2.        Hong Zhang, Zongwei Guo, Yafei Guo, Ziqian Wang, Yao Tang, Ting Song *, Zhichao Zhang*. Bim transfer between Bcl-2-like protein and Hsp70 underlines Bcl-2/Hsp70 crosstalk to regulate apoptosis. Biochemical Pharmacology 190 (2021) 114660

3.        Song, T ,  Guo,Y, Xue Z, Zongwei Guo, Wang,Z, Lin D, Zhang H, Pan H, Zhang,X, Yin F, Wang H, Bonnette U, and Zhang ZC*. Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance. Leukemia. https://doi.org/10.1038/s41375-021-01283-5

4.        Wang, Z., Song, T, Guo, Z.,Laura, B.,Guo, Y., Zhang, H.,Wang, H.,Zhang, X., Pan, H., Ji, T., Yin, F.,  Zhou, S., Dai, J.and Zhang, Z*. (2021) A novel Hsp70 inhibitor specifically targeting the cancer-related Hsp70-Bim protein-protein interaction[J]. European Journal of Medicinal Chemistry.220,113452.

5.        Guo, ZW, Song, T, Zhang ZC*. Systems analysis of the ‘weights’ of Bcl-2 and Mcl-1 in mitochondrial apoptosis pathway establishes a predictor for best drug combination ratio. Quantitative Biology. Accepted.

6.        Wang ZQ, Song, T, Zhang ZC*.Targeting the allosteric pathway that interconnect the core-functional scaffold and the distal phosphorylation sites for specific dephosphorylation of Bcl-2. Journal of medicinal chemistry. 2020, 63, 13733-13744.

7.        Guo, ZW, Song, T, Wang, ZQ., Lin, DH, Cao, KK., Liu, P, Feng YG, Zhang XD, Wang P, Yin FK, Dai J, Zhou S, Zhang ZC*. The chaperone Hsp70 is a BH3 receptor activated by the pro-apoptotic Bim to stabilize anti-apoptotic clients. The Journal of Biological Chemistry, 2020, 295, 12900-12909.

8.        Zhang XD, Wang ZQ, Guo ZW, Song T , He NZ, Zhu JJ, Cao KK, and Zhang ZC*. A “three-in-one” multi-functional probe for Bcl-2/Mcl-1 profiling and visualizing in situ. ChemBioChem, 2021, 22, 326-329. (81903462 and 81430083)

9.        Zhu JJ, Wang ZQ, Guo ZW, Zhang XD, Song T, Guo YF, Ji T, Zhang ZC*. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors. Arch Pharm, 2020. 353(5), e2000005.

10.    Guo ZW, Song T, Xue ZG, Liu P, Zhang MH, Zhang XD, Zhang ZC*. Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1. European Journal of Pharmaceutical Sciences, 2020, 142: 105105.

11.    Wang Peiran, Zhang ZC*. Identification of the apoptosis and autophagy bifunctional proteins, Molecular Informatics, 2019, 1900008.

12.    He NZ, Liu P, Wang ZQ, Guo ZW, Yan XX, Chen HB and Zhang ZC*. Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysis. Biochemical and Biophysical Research Communications, 2019, 512, 921-926.

13.    Zhang XD, Wang ZQ, Guo ZW, He NZ, Liu P, Xia DS, Yan XF and Zhang ZC*. A novel turn-on fluorescent probe for selective sensing and imaging of glutathione in live cells and organisms. Analyst, 2019, 144, 3260-3266.

14.    Song T, Wang PR, Yu XY, Wang AH, Chai GB, Fan YD and Zhang ZC*. Systems analysis of phosphorylation-regulated Bcl-2 interactions establishes a model to reconcile the controversy over the significance of Bcl-2 phosphorylation. British journal of pharmacology, 2019, 176, 491-504.

15.    Song Ting, Cao Keke, Fan Yu dan, Zhichao Zhang,*, Zong W. Guo, Min H. Zhang and Peng Liu. Expression and Solution NMR Study of Multi-site Phosphomimetic Mutant BCL-2 Protein. Protein & Peptide Letters, 2019, 26, 449-457. (21402022,21372036, 81570129,21502015, and 81430083).

16.    Ziqian Wang, Zhichao Zhang*, Ting Song, Zongwei Guo, Affinity-based probe reveal Bim negatively regulates the chaperone functions of Hsp70, a non-Bcl-2 BH3 receptor. Cancer Research 2019, 79(13), S2754.(这是个会议摘要。没有致谢)

17.    Wang ZQ, Guo ZW, Song T, Zhang, XD, He NZ, Liu P, Wang PR and Zhang ZC*. Proteome-wide identification of on- and off-targets of Bcl-2 inhibitors in native biological systems by using affinity-based probes (AfBPs). Chembiochem, 2018, 21, 2312-2320.

18.    Song T, Zhang MH, Liu P, Xue ZY, Fan YD, and Zhang ZC*, Identification of JNK1 as a predicting biomarker for ABT-199 and paclitaxel combination treatment. Biochemical pharmacology, 2018, 155, 102-109.

19.    刘璐 张志超. 线性短模体：介导蛋白质相互作用的新模块.生物化学与生物物理进展2017, 44, 129-138

20.    Wang ZQ, Xu WJ, Song T, Guo ZW, Liu L, Fan YD, Wang AH and Zhang ZC*. Fragment-based design, synthesis, and biological evaluation of 1-substituted-indole-2-carboxylic acids as selective Mcl-1 inhibitors. Archiv der Pharmazie, 2017, 350, 1-12.

21.    Song T, Wang ZQ, Ji FL, Feng YG, Fan YD, Chai GB, Li XQ, Li ZQ and Zhang ZC*. Deactivation of Mcl-1 by dual-function small-molecule inhibitors targeting Bcl-2 homology 3 domain and facilitating Mcl-1 ubiquitination. Angewandte chemie international edition, 2016, 55, 14248-1425.

22.    Song T, Wang ZQ and Zhang ZC*. Substituted indole Mcl-1 inhibitors: a patent evaluation. Expert opinion on therapeutic patents, 2016, 26, 1227-1238.

23.    Wang ZQ, Song T, Feng YG, Guo ZW, Fan YD, Xu WJ, Liu L, Wang AH and Zhang ZC*.  Bcl-2/MDM2 dual inhibitors based on universal pyramid-like α-helical mimetics. Journal of medicinal chemistry, 2016, 59, 3152-3162.

24.      Wang AH, Song T, Wang ZQ, Liu YB, Fan YD, Zhang YH and Zhang ZC*. Mechanism of Mcl-1 conformational regulation upon small molecule binding revealed by molecular dynamic simulation. Chemical biology & drug design, 2016, 87, 551-561.

25.    Zhang ZC*, Su PC, Li XQ, Song T, Chai GB, Yu XY and Zhang KR. Novel Mcl-1/Bcl-2 Dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic. Archiv. Der. Pharmazie, 2015, 348, 89-99.

26.    Song T, Yu XY, Liu YB, Li XQ, Chai GB and Zhang ZC*. Discovery of a small-molecule pBcl-2 inhibitor that overcomes pBcl-2-mediated resistance to apoptosis. Chembiochem, 2015, 16, 757-765.

27.    Song T, Chai GB, Liu YB, Xie MZ, Chen QB, Yu XY, Sheng HK and Zhang ZC*. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition. European Journal of Pharmaceutical Sciences, 2015, 70, 64-71. 

28.    Song T, Chai GB, Liu YB, Yu XY, Wang ZQ and Zhang ZC*. Bcl-2 phosphorylation confers resistance of chronic lymphocytic leukemia cells to the BH3 mimetic ABT-737, ABT-263 and ABT-199 by impeding direct binding. British journal of pharmacology, 2016, 171, 471-483. 

29.    Li XQ, Liang XM, Song T, Su PC and Zhang ZC*. Design, synthesis and structure–activity relationship studies of morpholino-1H-phenalene derivatives that antagonize Mcl-1/Bcl-2. Bioorganic & medicinal chemistry, 2014, 22, 5738-5746.

30.    Li XQ, Wang ZQ, Feng YG, Song T, Su PC, Chen QB , Chai GB, Yang Y and Zhang ZC*. Two-face, two-turn α-helix mimetics based on a cross-acridine scaffold: analogues of the Bim BH3 domain. Chembiochem, 2014, 15, 1280-1285.

31.    Huang X, Wang C, Li S, Liu YB and Zhang ZC*. Highly sensitive visualization of inorganic mercury in mouse neurons using a fluorescent probe. Journal of fluorescence, 2014, 24, 1313-1317.

32.    Song T, Yang Y, Wu GY, Xie SH, Su PC, Feng YG* and Zhang ZC*. Corrigendum to “3-Thiomorpholin-8-oxo-8H-acenaphtho [1, 2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1”. Bioorganic & Medicinal Chemistry, 2014, 22, 663-664.

33.    Liu YB and Zhang ZC*. Resistance to BH3 mimetic S1 in non-small cell lung cancer cells that phosphorylate Bim through ERK1/2 and lead to its proteasomal degradation. Journal. Thoracic Oncology, 2013, 8, S1061.

34.    Liu YB and Zhang ZC*. Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2. Journal thoracic oncology, 2013, 8, S767.

35.    Song T, Chen Q, Li XQ, Chai GB and Zhang ZC*. Correction to 3-thiomorpholin-8-oxo- 8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-Cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies. Journal of medicinal chemistry, 2013, 56, 9366-9367.

36.    Liu YB, Zhang ZC*, Song T, Liang FR, Xie MZ and Sheng HK. Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2. British journal of pharmacology, 2013, 169, 1612-1623.

37.    Liu YB, Li ZQ, Song T, Xue ZG and Zhang ZC*. Mechanisms of anti-leukemic activity of the Bcl-2 homology domain-3 mimetic S1. Biomedicine & Pharmacotherapy, 2013, 67, 583-591.

38.    Zhang ZC, Liang XM, Li XQ, Song T, Chen QB and Sheng HK. Design and application of a rigid quinazolone scaffold based on two-face Bim a-helix mimicking. European journal of medicinal chemistry, 2013, 69, 711-718.

39.    Zhang ZC *, Zhao Y, Song T, Liu YB, Li XQ, Su PC and Xie SH. Study of binding thermodynamics in the optimization of BH3 mimetics. Chemical biology & drug design, 2013, 82, 4, 394-400.

40.    Song T, Xue ZG, Zhang ZC*, Shen XY and Li XQ. Pan-BH3 mimetic S1 exhibits broad-spectrum antitumour effects by cooperation between Bax and Bak. Basic & clinical pharmacology & toxicology, 2013, 113, 145-151.

41.    Zhang ZC*, Liu YB, Song T, Xue ZG, Shen XY, Liang FR, Zhao Y, Li ZQ and Sheng HK.  An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1. British journal of cancer, 2013, 108, 1870-1878.

42.    Zhang ZC*, Liu CW, Li XQ, Song T, Wu ZY, Liang XM, Zhao Y, Shen XY and Chen HB*. Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors. European journal of medicinal chemistry, 2013, 60, 410-420.

43.    Song T, Li XQ, Chang XL, Liang XM, Zhao Y, Wu GY, Xie SH, Su PC, Wu ZY, Feng YG, Zhang ZC*. 3-thiomorpholin-8-oxo-8H-acenaphtho [1, 2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1. Bioorganic & medicinal chemistry, 2013, 21, 11-20.

44.    Zhang ZC*, Song T, Li XQ, Wu ZY, Feng YG, Xie FB, Liu CW, Qin JQ and Chen HB. Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E, E)-2 (benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach. European journal of medicinal chemistry, 2013, 59, 141-149.

45.    Zhang ZC*, Li XQ, Song T, Zhao Y and Feng YG. An anthraquinone scaffold for putative, two-face Bim BH3 α-helix mimicries. Journal of medicinal chemistry, 2012, 55, 10735-10741. 

46.    Song T, Chang XL, Zhang ZC*, Liu YB and Shen XY. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak. Journal of pharmacological sciences, 2012, 119, 330-340.  

47.    Zhong JT, Xu Y, Yi HW, Su J, Yu HM, Xiang XY, Li XN, Zhang ZC* and Sun LK*. The BH3 mimetic S1 induces autophagy through ER stress and disruption of Bcl-2/Beclin 1 interaction in human glioma U251 cells. Cancer letters, 2012, 323, 180-187.

48.    李亚平, 钟加滕, 张志超, 衣豪伟, 李晓宁, 崔丽丽. Bcl-2抑制剂S1通过内质网途径诱导黑色素瘤B16细胞凋亡的机制. 中国老年学杂志, 2012, 04, 767-769.

49.    琴瀚姣, 刘宁, 张晶, 张钰, 杨晓春, 张志超, 孙连坤. Bcl-2抑制剂S1诱导人卵巢癌细胞凋亡及其机制的研究. 吉林医学, 2012, 13, 2693-2695.

50.    Zhang ZC*, Yang HN, Wu GY, Li ZQ, Song T and Li XQ. Probing the difference between BH3 groove of Mcl-1 and Bcl-2 protein: implications for dual inhibitors design. European journal of medicinal chemistry, 2011, 46, 3909-3916.

51.    Zhang ZC*, Wu GY, Xie FB, Song T and Chang XL.  3-Thiomorpholin-8-oxo-8H-acenaphtho [1, 2-b] pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies. Journal of medicinal chemistry, 2011, 54, 1101-1105.

52.    Zhang ZC*, Song T, Zhang TT, Wu GY, An LJ and Du GH. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1. International journal of cancer, 2011, 128, 1724-1735.

53.    Zhang ZC*, Wu GY, Gao J and Song T. Inclusion complex of a Bcl-2 inhibitor with cyclodextrin: characterization, cellular accumulation, and in vivo antitumor activity. Molecular pharmaceutics, 2010, 7, 1348-1354.

54.    Zhang ZC*, Gao J, Wang YY, Song T, Zhang J, Wu GY, Zhang TT and Du GH. Tanshinone IIA triggers p53 responses and apoptosis by RNA polymerase II upon DNA minor groove binding. Biochemical pharmacology, 2009, 78, 1316-1322.

55.    Zhang ZC, Wang YY, Song T, Gao J, Wu GY, Zhang J and Qian XH. DNA double helix unwinding triggers transcription-block-dependent apoptosis: A semi-quantitative probe of the response of ATM, RNAPII, and p53 to two DNA intercalators. Chemical research in toxicology, 2009, 22, 483-491.

56.    Li YC, Zhang ZC*, Song T and Wu GY. Characterization of DNA intercalator bound to calf thymus DNA: ionic strength and pH value effect. Chemical research in chinese universities, 2009, 25, 497-499.

57.    Zhang ZC*, Zhang J, Jin LJ, Song T, Wu GY and Gao J. Tanshinone IIA Interacts with DNA by Minor Groove-binding. Biological and Pharmaceutical Bulletin, 2008, 31, 2342-2345.

58.    Zhang ZC*, Wang YY, Zhang J, Song T and Qian XH. Potency and property of DNA conformational damage determine ATM activation: two new DNA topological probes. Cell Biochemistry and Function, 2008, 26, 808-812.

59.    Zhang ZC*, Zhang J, Yuan CL, Wu GY and Qian XH. Intercalation, cytotoxicity and molecular modeling of acenaphtho [1, 2-b] pyrrole chromophores as new family of antitumor agents. Chemical research in chinese universities, 2008, 24, 449-453.

60.    Jin LJ, Zhang ZC*, Wang YY, Wei MJ and Xu Q. A novel small molecule inhibitor targeted at Bcl-2. Science in China Series C: Life Sciences, 2007, 50, 624-629.

61.    金礼吉, 张志超*, 王媛媛, 魏美娇, 徐芹. 一个新的有机小分子Bcl-2蛋白抑制剂. 中国科学, 2007, 37, 416-421.  

62.    杨源源, 张志超*, 盛辉, 刘凤玉, 钱旭红, 徐芹, 张晶.  一种苊并杂环有机小分子嵌入DNA的几何学模式研究. 高等学校化学学报, 2007, 28, 453-457.

63.     Zhang ZC*, Jin LJ, Qian XH, Wei MJ, Wang YY, Wang J, Yang YY, Xu Q, Xu YT and Liu FY. A novel non-intercalator apoptosis-inducing organic compound via Bcl-2 protein and structure-based development of Bcl-2 inhibitor. Chembiochem, 2007, 8, 113-121.

64.    Zhang ZC, Yang YY, Zhang DN, Wang YY, Qian XH and Liu FY. Acenaphtho [1, 2-b]pyrrole derivatives as new family of intercalators: Various DNA binding geometry and interesting antitumor capacity. Bioorganic & medicinal chemistry, 2006, 14, 6962-6970.

65.    Zhang ZC, Yang YY, Liu FY, Qian XH and Xu Q. Study on the interaction between   4-(2-diethylamino-ethylamino)-8-oxo-8H-acenaphtho [1, 2-b] pyrrole-9-carbonitrile and DNA by molecular spectra. International journal of biological macromolecules, 2006, 38, 59-64.

66.    Zhang ZC, Wu D, Guo XF, Qian XH, Lu Z, Xu Q, Yang YY, Duan LP, He YK and Feng Z. Visible study of mercuric ion and its conjugate in living cell of mammalian and plant. Chemical research in toxicology, 2005, 18, 1814-1820.

 

专利

1.        4-取代萘酰亚胺类化合物及其应用 20171058107.3 授权日：2021，8，4

2.        一类1,5-二苯基吡唑-3-羧酸类化合物及其应用. 2152047739.5. 授权日: 2017, 10, 24.

3.        苯并咪唑类化合物及其应用. ZL 2014 1 0326318.9. 授权日: 2016, 12, 7.

4.        一类吖啶化合物及其应用. 201410150928.8. 第一发明人. 授权日: 2016, 4, 13.

5.        苊并杂环类化合物及其诱导细胞凋亡和抗肿瘤的应用. ZL200410050449.5. 第二发明人.

6.  苊并杂环类化合物、其环糊精包合物和环糊精配结物以及它们在制备Bcl-2家族蛋白抑制剂中的应用. CN200910209961.2. 第一发明人. 已授权.授权日：2012, 9, 5.

7. 苊并杂环类化合物、其环糊精包合物和环糊精配结物以及它们在制备Bcl-2家族蛋白抑制剂中的应用. PCT/CN2009/074602.目前已经进入美、欧、日、俄罗斯、乌克兰、新西兰、墨西哥、南非等32个国家和地区。第一发明人.

8.  Bcl-2家族蛋白抑制剂，其环糊精包合物、配结物及其在制备Bcl-2家族蛋白抑制剂中的应用. PCT/CN2010/075521. 第一发明人.

9. 一类氨基取代苊并杂环化合物及其应用. 中国专利: 201110191880.1. 第一发明人. 已授权.授权日：2013, 9, 10.

10．一类苊并杂环化合物及其应用. 中国专利：201110191883.5, 第一发明人, 已授权. 授权日: 2013, 6, 15.

11. 一类苊并杂环化合物及其应用. PCT/CN2011/077682, 第一发明人.

12.  (E,E)-2-(苯甲基氨基羰基)-3-苯乙烯基丙烯腈及其衍生物的应用. 201110077548.2, 第一发明人.

13. 筛选能够被苊并杂环类化合物诱导凋亡的肿瘤细胞的方法及其应用. PCT/CN2011/000119.

14. 一类蒽醌类化合物及其应用. 201210218670.1, 已授权. 授权日: 2014, 5, 6.

15. Acenaphtho heterocyclic compounds and application thereof. 申请号: 13810.901, 授权日: 2013, 1, 18.

2020申请专利：

1.     申  请  号：202010044449.3发明名称：一类非那烯酮类化合物及其应用 申请日期：2020.1.15

2.     申  请  号：2020102979197 发明名称：3-氰基非那烯酮类化合物及其应用 申请日期：2020.4.16

3.     2-氰基非那烯酮类化合物及其在白血病治疗中的应用。 2021年申请，202110164854.3